CANDLE/PRAAS患者中巴瑞替尼减量后的疾病发作及发作标准制定
在10例CANDLE/PRAAS患者中,9例共14次巴瑞替尼减量,7/14次(50%)减量后出现疾病发作,所有4次减量>25%均触发了发作(p<0.05);低剂量访视时发作标准达标率43.14% vs 高剂量访视12.75%(p<0.0001),加用干扰素评分作为额外发作标准可提高检测敏感性。
要点
- 9例患者14次巴瑞替尼减量中7次(50%)出现疾病发作。
- 所有4次减量>25%均触发疾病发作(p<0.05)。
- 低剂量访视发作标准达标率43.14% vs 高剂量访视12.75%(p<0.0001)。
核心结论
- 观察到巴瑞替尼减量后出现疾病发作和炎症反弹,并提出可协助监测疾病活动和设计CANDLE/PRAAS临床研究的发作标准。
研究设计与样本
- 开放标签扩展准入项目中10例CANDLE/PRAAS患者接受巴瑞替尼治疗,2014年4月至2019年12月间9例患者共减量14次。
- 回顾性分析减量前后每日日记评分和实验室标志物,制定「临床」和「亚临床」发作标准。
- 用双侧χ2检验比较减量<25%与>25%患者的发作率,以及推荐「优化」剂量访视(高剂量访视)与低于推荐剂量访视(低剂量访视)的发作标准达标率。
主要发现
- 9/10例CANDLE患者减量,7/14次(50%)减量导致疾病发作。
- 所有4次>25%减量均触发疾病发作(p<0.05)。
- 低剂量访视时43.14%达到发作标准,高剂量访视时12.75%达到发作标准(p<0.0001)。
- 加用干扰素评分作为额外发作标准提高了检测疾病发作的敏感性。
关键数值与推荐
- 减量>25%触发疾病发作(p<0.05)。
- 低剂量访视发作标准达标率43.14% vs 高剂量访视12.75%(p<0.0001)。
- 加用干扰素评分作为额外发作标准可提高检测敏感性。
临床怎么用
- 作者提出发作标准可协助监测CANDLE/PRAAS疾病活动并设计临床研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Patients with chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS) respond to the janus kinase inhibitor 1/2 inhibition with baricitinib at exposures higher than in rheumatoid arthritis. Baricitinib dose reductions to minimise exposure triggered disease flares which we used to develop 'flare criteria'. METHODS: Of 10 patients with CANDLE/PRAAS treated with baricitinib in an open-label expanded-access programme, baricitinib doses were reduced 14 times in 9 patients between April 2014 and December 2019. Retrospective data analysis of daily diary scores and laboratory markers collected before and after the dose reductions were used to develop 'clinical' and 'subclinical' flare criteria. Disease flare rates were compared among patients with <25% and >25% dose reductions and during study visits when patients received recommended 'optimized' baricitinib doses (high-dose visits) versus lower than recommended baricitinib doses (low-dose visits) using two-sided χ2 tests. RESULTS: In the 9/10 patients with CANDLE with dose reduction, 7/14 (50%) times the dose was reduced resulted in a disease flare. All four dose reductions of >25% triggered a disease flare (p <0.05). Assessment of clinical and laboratory changes during disease flares allowed the development of disease flare criteria that were assessed during visits when patients received high or low doses of baricitinib. Disease flare criteria were reached during 43.14% of low-dose visits compared with 12.75% of high-dose visits (p <0.0001). Addition of an interferon score as an additional flare criterion increased the sensitivity to detect disease flares. CONCLUSION: We observed disease flares and rebound inflammation with baricitinib dose reductions and proposed flare criteria that can assist in monitoring disease activity and in designing clinical studies in CANDLE/PRAAS.
引用
- Cetin Gedik K, Ortega-Villa AM, Materne G, et al. Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE/PRAAS. Ann Rheum Dis. 2024. PMID: 38653530. doi:10.1136/ard-2023-225463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。